Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 11 de 11
Filtrar
Más filtros










Base de datos
Intervalo de año de publicación
1.
Ann Med Surg (Lond) ; 85(11): 5568-5576, 2023 Nov.
Artículo en Inglés | MEDLINE | ID: mdl-37915682

RESUMEN

Background: A plethora of monkeypox papers have been published; however, pinpointing key and pivotal studies can be challenging amongst the ever-expanding literature. Bibliometric analyses are helpful in identifying the most influential articles and their impact pertinent to this field, which has helped mould the recognition and management of monkeypox. Methods: The Web of Science Core Collection (WoSCC) was searched on 27 October 2022. The top 100 most-cited articles on monkeypox were identified and evaluated by author, country, institution, type of articles, theme, journal of publication, keywords, and citations. Results: The top 100 most-cited studies were published between 1997 and 2022, and the 5-year period with the largest number of articles was 2007-2011. The median number of citations among the top 100 most-cited articles was 78.23. Of the top 100 most-cited studies, 91 were original articles, and nine were reviews, the median of annual citations was significantly higher in the review group than the original group, 7.86 (4.20-13.80) versus 4.50 (3.07-7.59; P=0.023). The 100 articles were classified into different research theme, with the top three being Immunology (31%), Infectious Diseases (30%), and Virology (26%), respectively. The keywords with the highest co-occurrence frequency were "monkeypox", "smallpox," and "smallpox virus." The largest number of articles in the top 100 were published in Emerging Infectious Diseases (n=13), followed by Journal of Virology (n=11), Journal of Infectious Diseases (n=5), and PLoS One (n=5). The authors identified 711 different authors from 195 institutions and 28 countries in the top 100 most-cited articles, with the majority based in the USA. Conclusion: The top 100 most-cited studies provide an important insight into the historical developments of monkeypox. The authors should strengthen the recognition and management of monkeypox worldwide and strengthen research cooperation among scholars in order to better respond to the ongoing or future outbreak.

2.
Thorac Cancer ; 14(12): 1059-1070, 2023 04.
Artículo en Inglés | MEDLINE | ID: mdl-36922372

RESUMEN

BACKGROUND: Previous studies have suggested the applicability of three classifications of subsolid nodules (SSNs). However, few studies have unraveled the natural history of the three types of SSNs. METHODS: A retrospective study from two medical centers between November 2007 and November 2017 was conducted to explore the long-term follow-up results of three different types of SSNs, which were divided into pure ground-glass nodules (pGGNs), heterogeneous ground-glass nodules (hGGNs), and real part-solid nodules (rPSNs). RESULTS: A total of 306 consecutive patients, including 361 SSNs with long-term follow-up, were reviewed. The median growth times of pGGNs, hGGNs, and rPSNs were 7.7, 6.0, and 2.0 years, respectively. For pGGNs, the median period of development into rPSNs was 4.6 years, while that of hGGNs was 1.8 years, and the time from pGGNs to hGGNs was 3.1 years (p < 0.05). In SSNs with an initial lung window consolidation tumor ratio (LW-CTR) >0.5 and mediastinum window (MW)-CTR >0.2, all cases with growth were identified within 5 years. Meanwhile, in SSNs whose LW-CTR and MW-CTR were 0, it took over 5 years to detect nodular growth. Pathologically, 90.6% of initial SSNs with LW-CTR >0 were invasive carcinomas (invasive adenocarcinoma and micro-invasive adenocarcinoma). Among patients with rPSNs in the initial state, 100.0% of the final pathological results were invasive carcinoma. Cox regression showed that age (p = 0.038), initial maximal diameter (p < 0.001), and LW-CTR (p = 0.002) were independent risk factors for SSN growth. CONCLUSIONS: pGGNs, hGGNs, and rPSNs have significantly different natural histories. Age, initial nodule diameter, and LW-CTR are important risk factors for SSN growth.


Asunto(s)
Adenocarcinoma , Neoplasias Pulmonares , Nódulos Pulmonares Múltiples , Lesiones Precancerosas , Humanos , Estudios Retrospectivos , Estudios de Seguimiento , Tomografía Computarizada por Rayos X/métodos , Nódulos Pulmonares Múltiples/patología , Neoplasias Pulmonares/patología
3.
Front Oncol ; 13: 1276095, 2023.
Artículo en Inglés | MEDLINE | ID: mdl-38322291

RESUMEN

Introduction: Treatments for multiple ground-glass opacities (GGOs) for which the detection rate is increasing are still controversial. Next-generation sequencing (NGS) may provide additional key evidence for differential diagnosis or optimal therapeutic schedules. Case presentation: We first reported a rare case in which more than 100 bilateral pulmonary GGOs (91.7% of the GGOs were pure GGOs) were diagnosed as both multiple primary lung cancer and intrapulmonary metastasis. We performed NGS with an 808-gene panel to assess both somatic and germline alterations in tissues and plasma. The patient (male) underwent three successive surgeries and received osimertinib adjuvant therapy due to signs of metastasis and multiple EGFR-mutated tumors. The patient had multiple pure GGOs, and eight tumors of four pathological subtypes were evaluated for the clonal relationship. Metastasis, including pure GGOs and atypical adenomatous hyperplasia, was found between two pairs of tumors. Circulating tumor DNA (ctDNA) monitoring of disease status may impact clinical decision-making. Conclusions: Surgery combined with targeted therapies remains a reasonable alternative strategy for treating patients with multifocal GGOs, and NGS is valuable for facilitating diagnostic workup and adjuvant therapy with targeted drugs through tissue and disease monitoring via ctDNA.

4.
Zhongguo Fei Ai Za Zhi ; 24(6): 447-452, 2021 Jun 20.
Artículo en Chino | MEDLINE | ID: mdl-34157804

RESUMEN

Lung cancer is the most common malignant tumor and the leading cause of cancer-related death worldwide. Most of the patients have distant metastasis when visiting the doctor, which seriously affects the survival time and quality of life of the patients. With the development of molecular targeted drugs, lung cancer treatment has been transformed from traditional chemotherapy to targeted therapy and precision medicine has been gradually applied in clinical practice, which can make lung cancer patients live longer and have a better quality of life. We present a case of advanced lung cancer patient who presented to Department of Thoracic Surgery of Beijing Haidian Hospital five years ago. We chose the reasonable treatment options though the genetic tests and circulating tumor DNA tests. We summarized the adverse reactions in the whole course of treatment. The comprehensive therapy we utilized, including targeted therapy, chemotherapy, antiangiogenic agents and local radiotherapy, have resulted in our patient with remaining alive. For advanced non-small cell lung cancer with epidermal growth factor receptor (EGFR) mutation positive, individualized treatment was conducted based on precise genotyping and dynamic monitoring, which can not only control the tumor, but also have mild toxic and side effects. The survival time of the patients was prolonged and the quality of life was guaranteed.
.


Asunto(s)
Carcinoma de Pulmón de Células no Pequeñas , Neoplasias Pulmonares , Inhibidores de Proteínas Quinasas/uso terapéutico , Antineoplásicos/efectos adversos , Antineoplásicos/uso terapéutico , Carcinoma de Pulmón de Células no Pequeñas/sangre , Carcinoma de Pulmón de Células no Pequeñas/diagnóstico , Carcinoma de Pulmón de Células no Pequeñas/genética , Carcinoma de Pulmón de Células no Pequeñas/terapia , ADN Tumoral Circulante/sangre , Terapia Combinada , Receptores ErbB/genética , Humanos , Neoplasias Pulmonares/sangre , Neoplasias Pulmonares/diagnóstico , Neoplasias Pulmonares/genética , Neoplasias Pulmonares/terapia , Inhibidores de Proteínas Quinasas/efectos adversos , Calidad de Vida , Resultado del Tratamiento
5.
Front Oncol ; 11: 653988, 2021.
Artículo en Inglés | MEDLINE | ID: mdl-34109114

RESUMEN

OBJECTIVE: The incidence of early stage multiple primary lung cancer (MPLC) has been increasing in recent years, while the ideal strategy for its diagnosis and treatment remains controversial. The present study conducted genomic analysis to identify a new molecular classification method for accurately predicting the diagnosis and therapy for patients with early stage MPLC. METHODS: A total of 240 tissue samples from 203 patients with multiple-non-small-cell lung cancers (NSCLCs) (n = 30), early stage single-NSCLC (Group A, n = 94), and advanced-stage NSCLC (Group B, n = 79) were subjected to targeted multigene panel sequencing. RESULTS: Thirty patients for whom next-generation sequencing was performed on >1 tumor were identified, yielding 45 tumor pairs. The frequencies of EGFR, TP53, RBM10, ERBB2, and CDKN2A mutations exhibited significant differences between early and advanced-stage NSCLCs. The prevalence of the EGFR L858R mutation in early stage NSCLC was remarkably higher than that in advanced-stage NSCLC (P = 0.047). The molecular method classified tumor pairs into 26 definite MPLC tumors and four intrapulmonary metastasis (IM) tumors. A high rate of discordance in driver genetic alterations was found in the different tumor lesions of MPLC patients. The prospective Martini histologic prediction of MPLC was discordant with the molecular method for three patients (16.7%), particularly in the prediction of IM (91.7% discordant). CONCLUSIONS: Comprehensive molecular evaluation allows the unambiguous delineation of clonal relationships among tumors. In comparison, the Martini and Melamed criteria have notable limitations in the recognition of IM. Our results support the adoption of a large panel to supplement histology for strongly discriminating NSCLC clonal relationships in clinical practice.

6.
Cancer Manag Res ; 13: 1767-1776, 2021.
Artículo en Inglés | MEDLINE | ID: mdl-33642878

RESUMEN

OBJECTIVE: This study set out to investigate the effect of miR-1253 on lung cancer progression through targeted regulation of ANXA3. METHODS: RT-PCR was employed to detect the miR-1253 expression levels in lung cancer cells and its targeted gene ANXA3 mRNA determined by biological information prediction. MTT, invasion and apoptosis rate tests were employed to detect the proliferation, invasion and apoptosis rate of lung cancer cells over-expressing miR-1253 or those with low expression of ANXA3 and the expression of related proteins. RESULTS: RT-qPCR results manifested that the miR-1253 level was down-regulated in lung cancer tissues and cells, and the ANXA3 expression increased. The miR-1253 and ANXA3 expression levels were negatively correlated. miR-1253 was correlated with tumor differentiation degree, TNM stage and lymph node metastasis of lung cancer patients. Cell tests confirmed that miR-1253 played a tumor-inhibiting function, including inhibiting proliferation and invasion of lung cancer cells and promoting apoptosis. Bioinformatics prediction and subsequent experiments proved that ANXA3 was the direct target of miR-1253. Moreover, after the ANXA3 expression in lung cancer cells was knocked down, proliferation and invasion of those cells were inhibited dramatically, the apoptosis rate increased markedly, and the expression levels of pro-apoptosis-related proteins Bax and caspase-3 were up-regulated, and the anti-apoptosis-related protein Bcl-2 expression was down-regulated. CONCLUSION: miR-1253 can inhibit the proliferation and invasion of lung cancer cells and promote their apoptosis by targeting ANXA3. It can be used as a new potential target for lung cancer treatment.

7.
Thorac Cancer ; 11(4): 943-949, 2020 04.
Artículo en Inglés | MEDLINE | ID: mdl-32061064

RESUMEN

BACKGROUND: We investigated the safety and feasibility of intraoperative near-infrared (NIR) imaging using indocyanine green (ICG) during sympathectomy in the management of primary palmar hyperhidrosis (PPH). METHODS: We performed a retrospective review of 142 patients (ICG group) who underwent endoscopic thoracic sympathectomy (ETS) between February 2018 and April 2019. All patients received a 5 mg/kg infusion of ICG 24 hours preoperatively. The vital signs before and after ICG injection and adverse reactions were recorded. Meanwhile, 498 patients (Non-ICG group) who underwent ETS by normal thoracoscopy during August 2017 to April 2019 were also reviewed to compare the abnormal white blood cell (WBC) counts, alanine transaminase (ALT), aspartate transaminase (AST), blood urea nitrogen (BUN), and creatinine (Cr) levels before and after operation between two groups. RESULTS: For ICG group, the vital signs including body temperature, heart rate and blood pressure before and after ICG injection were stable. There was no significant difference in the abnormal WBC counts, ALT, AST, BUN, and Cr levels before and after operation between two groups. Only one patient had mild adverse reaction (0.7%) after ICG injection. The visibility rate of all sympathetic ganglions was 96.7% (1369/1415). The visibility rate from T1 to T5 was 98.23% (278/283), 98.23% (278/283), 97.17% (275/283), 95.76% (271/283), and 94.35% (267/283), respectively. There was no significant difference in the visibility rate with regard to age, gender, height, weight, body mass index, and PPH grade. CONCLUSIONS: NIR fluorescence imaging with ICG for identifying sympathetic ganglions is relatively safe and feasible. KEY POINTS: • Significant findings of the study. NIR fluorescence imaging with ICG for identifying sympathetic ganglions is relatively safe and feasible. • What this study adds. This technology may take the place of the rib-oriented method as standard practice for the precise localization of sympathetic ganglions, and may improve the effect of sympathectomies.


Asunto(s)
Hiperhidrosis/cirugía , Verde de Indocianina/metabolismo , Cuidados Intraoperatorios , Imagen Óptica/métodos , Simpatectomía/métodos , Procedimientos Quirúrgicos Torácicos/métodos , Toracoscopía/métodos , Adulto , Estudios de Factibilidad , Femenino , Fluorescencia , Estudios de Seguimiento , Humanos , Hiperhidrosis/diagnóstico por imagen , Hiperhidrosis/metabolismo , Hiperhidrosis/patología , Masculino , Pronóstico , Estudios Retrospectivos
8.
Ann Thorac Surg ; 98(5): 1790-6; discussion 1796, 2014 Nov.
Artículo en Inglés | MEDLINE | ID: mdl-25236367

RESUMEN

BACKGROUND: Mechanical pleurodesis is widely used to treat primary spontaneous pneumothorax to decrease postoperative recurrence after thoracoscopic bullectomy, but it is unclear whether it actually reduces primary spontaneous pneumothorax recurrence. We aimed to investigate the effectiveness of mechanical pleurodesis after thoracoscopic treatment of primary spontaneous pneumothorax. METHODS: In our parallel-group, prospective, randomized, controlled trail at 2 hospitals in China, 289 patients were enrolled from January 2010 to January 2013. Patients were randomly assigned (1:1) to receive thoracoscopic wedge resection only (WR group) or thoracoscopic wedge resection and mechanical pleurodesis (WR+MP group). This trial is registered with ClinicalTrial.gov (NCT01463553). RESULTS: Intraoperative bleeding and postoperative pleural drainage were significantly lower in the thoracoscopic WR only group. Postoperative recurrence rate did not significantly differ between groups (log-rank test p=0.791; Breslow test p=0.722). In the thoracoscopic WR only group, no recurrences were found when bullae were isolated or limited; recurrence was 7.5% with the presence of multiple bullae. Younger patients had an increased risk of recurrence (relative risk 3.015; 95% confidence interval 1.092 to 8.324). CONCLUSIONS: Thoracoscopic mechanical pleurodesis did not significantly decrease primary spontaneous pneumothorax recurrence compared with simple wedge resection, but intraoperative bleeding and postoperative pleural drainage rates were higher. Younger age increases the risk of recurrence.


Asunto(s)
Drenaje/métodos , Pleura/cirugía , Pleurodesia , Neumonectomía/métodos , Neumotórax/cirugía , Cirugía Torácica Asistida por Video/métodos , Femenino , Estudios de Seguimiento , Humanos , Masculino , Estudios Prospectivos , Recurrencia , Factores de Riesgo , Resultado del Tratamiento , Adulto Joven
9.
Ann Thorac Surg ; 95(2): e29-31, 2013 Feb.
Artículo en Inglés | MEDLINE | ID: mdl-23336911

RESUMEN

Pulmonary glomus tumors are extremely rare, with only 19 cases having been reported worldwide. The glomus body is considered to be related to the regulation of body temperature, but the reported cases were not associated with hyperpyrexia. Here, we describe a 28-year-old man with hyperpyrexia and anemia complicated with a coin lesion of the right lung. After resection of the upper lobe of the right lung by video-assisted thoracoscopic surgery, all of the patient's symptoms disappeared. The pathologic analysis reported a rare pulmonary glomus tumor. The disease had not recurred by 1 year after operation.


Asunto(s)
Anemia/etiología , Fiebre/etiología , Tumor Glómico/complicaciones , Neoplasias Pulmonares/complicaciones , Adulto , Humanos , Masculino
10.
Exp Biol Med (Maywood) ; 236(4): 483-91, 2011 Apr 01.
Artículo en Inglés | MEDLINE | ID: mdl-21454376

RESUMEN

Cisplatin-based chemotherapy is the standard therapy used to treat non-small-cell lung cancer. However, its efficacy is largely limited due to the development of drug resistance. The exact mechanism in which cancer cells develop resistance to the drug is not yet fully understood. The purpose of the present study is to test the role of volume-sensitive Cl(-) channels in cisplatin resistance in human lung adenocarcinoma cells (A549 cells) using patch-clamp recording, cell volume measurement and apoptosis assay. The results showed that cisplatin treatment induced an apoptotic volume decrease (AVD) and activated a Cl(-) current that showed properties similar to the volume-sensitive outward rectifying (VSOR) Cl(-) current in wild-type A549 cells. Both the AVD process and VSOR Cl(-) current were blocked by the chloride channel blocker 4,4'-diisothiocyanostilbene-2,2' disulfonic acid. However, the A549/CDDP cells, a model of acquired cisplatin resistance cells, on the other hand, had almost no AVD process and VSOR Cl(-) current when treated with cisplatin. Treatment of A549/CDDP cells with trichostatin A (TSA), a drug that inhibits histone deacetylases, partially restored the VSOR Cl(-) current and increased cisplatin-induced cell apoptosis rate. These results suggest that impaired activity of VSOR Cl(-) channels contributes to the cisplatin resistance in A549/CDDP cells.


Asunto(s)
Adenocarcinoma/metabolismo , Antineoplásicos/farmacología , Canales de Cloruro/fisiología , Cisplatino/farmacología , Neoplasias Pulmonares/metabolismo , Adenocarcinoma/patología , Apoptosis , Secuencia de Bases , Línea Celular Tumoral , Cartilla de ADN , Resistencia a Antineoplásicos , Humanos , Ácidos Hidroxámicos/farmacología , Neoplasias Pulmonares/patología , Técnicas de Placa-Clamp , Reacción en Cadena de la Polimerasa de Transcriptasa Inversa
11.
Cancer Biol Ther ; 9(11): 885-91, 2010 Jun 01.
Artículo en Inglés | MEDLINE | ID: mdl-20339322

RESUMEN

The purpose of the present study is to observe the role of volume-sensitive Cl(-) channels in carboplatin-induced apoptosis in the human lung adenocarcinoma cell line A549 cells. Using patch clamp and apoptosis assays, we found that A549 cells underwent the process of apoptotic volume decrease (AVD) and apoptosis when treated with carboplatin or staurosporine (STS). This AVD and apoptosis process were blocked by chloride channel blockers, 4,4'-diisothiocyanostilbene-2,2'-disulfonic acid (DIDS) and 5-nitro-2-(3-phenyl propylamino)-benzoate (NPP B). Both carboplatin and STS treatment activated a Cl(-) current, which shows similar properties to hypotonicity-induced volume-sensitive Cl(-) current in A549 cells. In addition, carboplatin pretreatment augmented the magnitude of the hypoosmotic-induced volume-sensitive Cl(-) current. These results suggest that volume-sensitive Cl(-) channels may be responsible for the carboplatin-induced apoptosis in A549 cells by inducing the AVD process.


Asunto(s)
Apoptosis/efectos de los fármacos , Carboplatino/farmacología , Canales de Cloruro/fisiología , Ácido 4,4'-Diisotiocianostilbeno-2,2'-Disulfónico/farmacología , Adenocarcinoma/patología , Adenocarcinoma/fisiopatología , Inhibidores de la Angiogénesis/farmacología , Antineoplásicos/farmacología , Apoptosis/fisiología , Línea Celular Tumoral , Canales de Cloruro/antagonistas & inhibidores , Humanos , Soluciones Hipotónicas/farmacología , Neoplasias Pulmonares/patología , Neoplasias Pulmonares/fisiopatología , Potenciales de la Membrana/efectos de los fármacos , Potenciales de la Membrana/fisiología , Nitrobenzoatos/farmacología , Técnicas de Placa-Clamp , Estaurosporina/farmacología
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA
...